Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) EPS (Weighted Average and Diluted): 2019-2024

Historic EPS (Weighted Average and Diluted) for ImmunityBio (IBRX) over the last 6 years, with Dec 2024 value amounting to -$0.62.

  • ImmunityBio's EPS (Weighted Average and Diluted) rose 50.00% to -$0.07 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.41, marking a year-over-year increase of 55.43%. This contributed to the annual value of -$0.62 for FY2024, which is 46.09% up from last year.
  • As of FY2024, ImmunityBio's EPS (Weighted Average and Diluted) stood at -$0.62, which was up 46.09% from -$1.15 recorded in FY2023.
  • Over the past 5 years, ImmunityBio's EPS (Weighted Average and Diluted) peaked at -$0.59 during FY2020, and registered a low of -$1.15 during FY2023.
  • In the last 3 years, ImmunityBio's EPS (Weighted Average and Diluted) had a median value of -$1.04 in 2022 and averaged -$0.94.
  • In the last 5 years, ImmunityBio's EPS (Weighted Average and Diluted) tumbled by 50.85% in 2021 and then skyrocketed by 46.09% in 2024.
  • Yearly analysis of 5 years shows ImmunityBio's EPS (Weighted Average and Diluted) stood at -$0.59 in 2020, then slumped by 50.85% to -$0.89 in 2021, then declined by 16.85% to -$1.04 in 2022, then decreased by 10.58% to -$1.15 in 2023, then soared by 46.09% to -$0.62 in 2024.